NASDAQ$SION
Sionna Therapeutics Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open
Briefing
SION reported Q4 2025, a net loss of $20.4M.
For Q4 2025, SION reported a net loss of $20.4M. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.
- Net loss $20.4M.
- SION MD&A covers liquidity, operating priorities, and sector risks.
- SION MD&A covers liquidity, operating priorities, and sector risks.
Headline financials
Revenue & EPS history
Sionna Therapeutics Inc · Revenue · Quarterly
$0
Forward guidance
The quarterly filing discusses operating priorities, capital returns, and sector risks.
Tailwinds
- MD&A highlights liquidity and core business trends.
- Segment commentary supports the earnings narrative.
Headwinds
- Macro or input-cost pressure may affect margins.
- One-time items can affect YoY comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 4 quarterly earnings reports · overlaid with Q4 2025
-0.4%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+15.4%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+13.4%
Q2 2025
Best reaction
-11.3%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -11.3% | -12.4% | -21.8% | |
| Q4 2025 | -7.2% | -1.7% | +13.0% | |
| Q3 2025 | -1.6% | +0.4% | +13.0% | |
| Q2 2025 | +13.4% | +17.8% | +32.8% | |
| Q1 2025 | +4.7% | +9.0% | +40.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro